.png)
Onco-Summaries: Daily Oncology Updates at a Glance
- Oncofocus Team
- Dec 8
- 1 min read
Updated: Dec 10
08/12/2025
Chimeric Therapeutics' CHM CDH17 received the FDA orphan drug designation for Gastric Cancer (Ref)
The US FDA granted the orphan drug designation to Chimeric Therapeutics' CHM CDH17 (CDH17-targeting CAR-T cell therapy) in the treatment of Gastric Cancer.
Dr Rebecca McQualter, CEO, Chimeric Therapeutics: “This is a great step forward in the development of CHM CDH17 to serve patients with gastric cancer, where there is a significant unmet need.”